The 510(k) pathway is FDA's mechanism for clearing medical devices that are substantially equivalent to a legally marketed predicate device. For BCI signal decoding software sold as a component of a Class II rehabilitation device, navigating this pathway requires understanding both what "substantially equivalent" means for software accessories and what the current landscape of cleared predicates looks like for non-invasive BCI applications.
This post is a factual discussion of the 510(k) pathway as it applies to BCI software components. It does not constitute regulatory advice, and it does not describe or imply any specific FDA submission or clearance status for Synaptiq software. Working through a 510(k) submission requires engagement with a qualified regulatory professional and, typically, a pre-submission meeting with FDA to align on the intended use classification and submission strategy before significant documentation effort is invested.
The regulatory landscape for BCI software accessories is actively evolving. FDA guidance documents, cleared predicates, and software-as-a-medical-device (SaMD) frameworks are all subject to revision. Treat this post as a starting-point orientation, not a current compliance reference.
Is BCI Decode Software a Medical Device?
Before asking which regulatory pathway applies, the threshold question is whether BCI signal decoding software meets FDA's definition of a medical device under 21 CFR Part 880 and the FD&C Act. The definition of a device includes "an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article" intended to diagnose, cure, mitigate, treat, or prevent disease or affect the structure or function of the body.
BCI signal decoding software that generates commands for a rehabilitation exoskeleton — and where those commands are intended to facilitate motor rehabilitation — fits within the definition of a device accessory under FDA's Software as a Medical Device (SaMD) framework. FDA's 2019 guidance "Developing the Function and Intended Use of Software" and the 2023 updates to the Digital Health Center of Excellence guidance clarify that software which controls or provides control functionality to a medical device (the exoskeleton) is itself subject to FDA oversight.
Critically, the classification of the software accessory inherits from the classification of the device it controls. A rehabilitation exoskeleton that delivers therapeutic movement assistance to patients with motor impairments is typically classified as a Class II medical device under 21 CFR Part 882 (neurological devices) or Part 890 (physical medicine devices), depending on its specific intended use. A software component accessory to a Class II device is generally also subject to Class II requirements — meaning 510(k) clearance before commercial distribution.
Finding a Predicate: The Landscape for Non-Invasive BCI
Substantial equivalence under 510(k) requires identifying a predicate device with the same intended use and either the same technological characteristics, or different technological characteristics that do not raise new safety or effectiveness questions. For non-invasive motor-imagery BCI software, the predicate landscape is limited but not empty.
Several classes of cleared devices are relevant as predicates:
Neurofeedback systems (21 CFR 882.5860): FDA has cleared various EEG-based neurofeedback devices that provide real-time feedback based on brain signal processing. These devices use EEG signal analysis to drive feedback outputs — conceptually similar to BCI decode, though typically with less precise motor imagery decoding and without direct actuator control. Cleared neurofeedback predicates establish the substantial equivalence basis for EEG-based brain signal processing in a therapeutic context.
Functional electrical stimulation (FES) control systems: FES devices for motor rehabilitation have cleared 510(k)s. Control software that adapts FES stimulation parameters based on patient input signals may provide a predicate basis for BCI-driven rehabilitation control, if the intended use overlap is sufficiently close.
Non-invasive BCI software accessories: As the BCI field has matured, a small number of non-invasive EEG-based BCI systems have entered the 510(k) database. A thorough search of the 510(k) database for product codes in the neurological device and physical medicine device categories should be conducted as part of predicate identification — the landscape changes as new clearances are granted, and a search conducted two years ago may not reflect current cleared predicates.
The predicate search should target not just the final cleared devices but also their 510(k) summaries, which describe the intended use, technological characteristics, and performance testing data that supported clearance. Understanding what testing was accepted by FDA for prior clearances is as valuable as identifying the predicates themselves.
Software Safety Classification Under 21 CFR Part 880 and the FDA SaMD Framework
FDA applies a risk-based framework to SaMD that maps to the IEC 62304 software safety classification in some respects but is not identical to it. FDA's SaMD classification framework (based on IMDRF guidance) categorizes software by the significance of the healthcare situation and the criticality of the software's output to clinical decision-making or device control.
For BCI software that controls an actuated rehabilitation exoskeleton, the criticality is high: the software output directly drives device action that could cause patient injury if incorrect. This places the software in a higher-risk SaMD category, which FDA may use to require additional clinical performance data beyond what is needed for lower-risk software predicates.
FDA's 2023 draft guidance on predetermined change control plans for SaMD is particularly relevant for BCI software teams considering online adaptive algorithms. FDA has signaled that SaMD that modifies its behavior based on incoming data (adaptive or learning software) may require a predetermined change control plan (PCCP) to document how changes to the software's algorithm are managed, validated, and communicated to users. This is the FDA-side counterpart to the IEC 62304 change control discussion in the software lifecycle context.
The Pre-Submission Meeting: Why It Is Non-Optional
FDA's pre-submission (formerly Q-Sub) program allows device manufacturers to meet with FDA before submitting a 510(k) to align on the submission strategy, predicate selection, and required testing. For novel device categories — and BCI motor control software is a relatively novel category with limited precedent — pre-submission meetings are not just beneficial, they are practically essential.
Without a pre-submission meeting, a 510(k) submission for a novel BCI software device risks receiving an "additional information" response from FDA requesting testing that was not anticipated in the original submission — a process that can add 6–12 months to the clearance timeline. FDA's feedback on predicate selection, intended use language, and required performance testing in the pre-submission stage prevents the most common submission errors.
The pre-submission process is also the right venue to discuss FDA's current thinking on adaptive BCI algorithms, the applicability of PCCP requirements, and the appropriate performance testing methodology (bench testing vs. clinical data, appropriate validation datasets, statistical requirements for classification performance claims).
What "Designed for Regulatory Pathway" Actually Means
Companies at early stages in medical device software development sometimes describe their products as "designed for FDA 510(k) pathway" or "designed for IEC 62304 compliance." It is worth being precise about what this means and what it does not mean.
Designing for a regulatory pathway means: the development process follows the lifecycle activities required by the applicable standards; the software architecture, testing, and documentation are structured in a way that supports a future regulatory submission; and the product's intended use and performance claims are scoped to avoid representations that would require evidence not yet available.
It does not mean: the product has been reviewed by FDA, cleared for clinical use, or independently verified to meet any regulatory standard. Regulatory claims in marketing materials that imply cleared status when clearance has not been obtained are a serious compliance issue — misrepresentation of regulatory status is a violation that FDA takes seriously.
The appropriate framing is transparent: development follows IEC 62304 lifecycle practices; the intended use is designed to align with the 510(k) pathway; clinical evaluation required for regulatory submission is planned as the clinical validation program matures. This framing is honest about the current state and positions the regulatory pathway appropriately for OEM partners evaluating the SDK for integration into their clearance-seeking devices.